Results 71 to 80 of about 24,724 (196)

Targeting the Menin–KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation

European Journal of Haematology, EarlyView.
ABSTRACT Acute leukemias characterized by a shared epigenetic dependency on the menin–KMT2A axis rely on aberrant HOX‐driven transcriptional programs that sustain leukemic self‐renewal and impair differentiation. This dependency is most evident in KMT2A‐rearranged and NPM1‐mutated acute myeloid leukemia (AML), but also extends to other HOX‐dependent ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Mamdouh Skafi, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia

International Journal of Nanomedicine, 2017
Thomas Briot,1,2 Emilie Roger,1 Nolwenn Lautram,1 Alexis Verger,1 Anne Clavreul,3,4 Frederic Lagarce1,2 1Micro & Nanomédecines Translationelles – MINT, UNIV Angers, INSERM 1066, CNRS 6021, Université Bretagne Loire, MINT IBS-CHU,
Briot T, Roger E, Lautram N, Verger A, Clavreul A, Lagarce F   +5 more
doaj  

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers [PDF]

, 2016
The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other ...
Buschbeck, Marcus, Diesch, Jeannine, Garz, Anne-Kathrin, Götze, Katharina S., Palau, Anna, Zwick, Anabel   +5 more
core   +2 more sources

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma: A Retrospective Study

Cancer Innovation, Volume 5, Issue 2, April 2026.
Compared to conventional chemotherapy, treatment with BV‐AVD ± R in CAYA Hodgkin lymphoma patients resulted in comparable response rates (ORR: 96.4% vs. 95.4%) but with a marked reduction in Grade 4 hematologic toxicity (25.6% vs. 61.2%). BV‐AVD monotherapy yielded a higher ORR than BV‐AVD + R (100% vs. 93.9%).
Mengqing Xie, Meng Yuan, Mengwei Ren, Jing Tian, Shengyu Zhou, Xiaohui He, Yan Qin, Peng Liu, Jianliang Yang, Mengyuan Han, Fei Ma, Sheng Yang, Sidan Li   +12 more
wiley   +1 more source

Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease

Cancer Management and Research, 2019
Qing Ya Wang,* Yuan Li,* Ze Yin Liang, Yue Yin, Wei Liu, Qian Wang, Yu Jun Dong, Yu Hua Sun, Wei Lin Xu, Han Yun Ren Department of Hematology, Peking University First Hospital, Peking University, Beijing, People’s Republic of China*These authors ...
Wang QY, Li Y, Liang ZY, Yin Y, Liu W, Wang Q, Dong YJ, Sun YH, Xu WL, Ren HY   +9 more
doaj  

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

Experimental Hematology & Oncology, 2020
Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carried out to compare the two agents.
Bingbing Wen, Weiwen You, Sitian Yang, Xin Du   +3 more
doaj   +1 more source

Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. [PDF]

PLoS ONE, 2014
Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established.
Xiao Li, Qiang Song, Yu Chen, Chunkang Chang, Dong Wu, Lingyun Wu, Jiying Su, Xi Zhang, Liyu Zhou, Luxi Song, Zheng Zhang, Feng Xu, Ming Hou   +12 more
doaj   +1 more source

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy [PDF]

, 2017
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies. In
Clarke, Kathryn M., Kettyle, Laura M., Mills, Ken I., Thompson, Alexander, Young, Christine S.   +4 more
core   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source